Skip to content

Examination of the efficacy and safety of Doripenem for hospital-aquired pneumonia

Examination of the efficacy and safety of Doripenem for hospital-aquired pneumonia - Examination of the efficacy and safety of Doripenem

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004408
Enrollment
80
Registered
2010-11-01
Start date
2010-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospital-acquired pneumonia patient

Interventions

we treat with 0.5g of Doripenem for an hour or more and it is intravenous dripped three times a day. If the improvement is obtained, the antibiotics administering is ended. If the improvement is not

Sponsors

Hamamatsu University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: It is assumed that it meets all the following requirements. 1:written informed-consent. 2:age above 15 years 3:In-patient 4:Patient who needs antibiotics injection 5:serum Creatinin is 2.0mg/dl or less 6:It is a classification by the adult hospital acqired pneumonia diagnosis and treatment guideline and it is a patient with hospital acqired pneumonia,classified as the middle syndrome group (B group) and the serious illness group (C group)

Exclusion criteria

Exclusion criteria: The patient who corresponds to either the following excludes it from the object of the examination 1:Patient who is administering valproate sodium 2:Patient who has the past of shock or hypersensitivity for this medicine 3:Patient with liver dysfunction AST(GOT):100IU/L or more, ALT(GTP):100IU/L or more 4:Patient who has disease of central nervous system or with the past of epilepsy 5:Patient who has allergy or serious side effect in betalactam system medicine 6:Patient who has been put in to examination once 7:Patient who participated in other clinical trials and clinical researches within four months in the past 8:Patient who needs using prohibition medicine 9:patient whom conducting of the examination doctor judged that pursuit of right evaluation and enough passage is impossible 10:Pediatrics 11:Patient who corresponds to PS4

Design outcomes

Primary

MeasureTime frame
Clinical effectiveness

Secondary

MeasureTime frame
safety profile, PK

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026